AMAnn-Sofie De Meulemeester

Ann-Sofie De Meulemeester

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ann-Sofie De Meulemeester has a total of 69 co-authors. Here are the top co-authors by number of shared publications:

  • Peter A. M. de Witte

    Laboratory for Molecular Biodiscovery, Department of Pharmaceutical and Pharmacological Sciences KU Leuven Leuven Belgium

    3 shared publications
  • Aleksandra Siekierska

    VirusBank Platform, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, 3001 Leuven, Belgium

    2 shared publications
  • Aleksandra Siekierska

    Laboratory for Molecular Biodiscovery, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven BE-3000, Belgium

    1 shared publication
  • Alexander Martin Heberle

    Institute of Biochemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, 6020 Innsbruck, Austria

    1 shared publication
  • Andreas von Deimling

    German Consortium of Translational Cancer Research (DKTK), Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany; Department of Neuropathology, Institute of Pathology, Heidelberg University, Heidelberg 69120, Germany

    1 shared publication
  • Andrew J. Cole

    Neurology, Massachusetts General Hospital, Boston

    1 shared publication

Latest Publications

  • WONOEP appraisal: Modeling early onset epilepsies

    by Ann‐Sofie De Meulemeester, Christopher Reid, Stéphane Auvin, Peter L. Carlen, Andrew J. Cole, Roza Szlendak, Rossella Di Sapia, Solomon L. Moshé, Raman Sankar, Terence J. O'BRien, et al.

    Epilepsy has a peak incidence during the neonatal to early childhood period. These early onset epilepsies may be severe conditions frequently associated with comorbidities such as developmental deficits and intellectual disability and, in a significant percentage of patients, may be medication‐resistant. The use of adult rodent models in the exploration of mechanisms and treatments for early life epilepsies is challenging, as it ignores significant age‐specific developmental differences. More recently, models developed in immature animals, such as rodent pups, or in three‐dimensional organoids may more closely model aspects of the immature brain and could result in more translatable findings. Although models are not perfect, they may offer a more controlled screening platform in studies of mechanisms and treatments, which cannot be done in pediatric patient cohorts. On the other hand, more simplified models with higher throughput capacities are required to deal with the large number of epilepsy candidate genes and the need for new treatment options. Therefore, a combination of different modeling approaches will be beneficial in addressing the unmet needs of pediatric epilepsy patients. In this review, we summarize the discussions on this topic that occurred during the XVI Workshop on Neurobiology of Epilepsy, organized in 2022 by the Neurobiology Commission of the International League Against Epilepsy. We provide an overview of selected models of early onset epilepsies, discussing their advantages and disadvantages. Heterologous expression models provide initial functional insights, and zebrafish, rodent models, and brain organoids present increasingly complex platforms for modeling and validating epilepsy‐related phenomena. Together, these models offer valuable insights into early onset epilepsies and accelerate hypothesis generation and therapy discovery.


  • Open Access

    The dissemination of Rift Valley fever virus to the eye and sensory neurons of zebrafish larvae is stat1 dependent

    by S. ter Horst, A. Siekierska, As. De Meulemeester, A. Cuvry, L. Cools, J. Neyts, P. de Witte, J. Rocha-Pereira

    The Rift Valley fever virus (RVFV) is listed by the WHO as priority disease and causes haemorrhagic fever, encephalitis, and permanent blindness. To study RVFV pathogenesis and identify small-molecule antivirals, we established a novel in vivo model using zebrafish larvae. Pericardial injection of RVFV resulted in ~ 4 log 10 viral RNA copies/larva, which was inhibited by antiviral 2′-fluoro-2′-deoxycytidine. The optical transparency of the larvae allowed detection of RVFV eGFP in the liver and sensory nervous system, including the optic tectum and retina, but not the brain or spinal cord. Thus, RVFV-induced blindness likely occurs due to direct damage to the eye and peripheral neurons, rather than the brain. Treatment with JAK-inhibitor ruxolitinib, as well as knockout of stat1a but not stat1b , enhanced RVFV replication to ~ 6 log 10 viral RNA copies/larva and ultra-bright livers, although without dissemination to sensory neurons or the eye, hereby confirming the critical role of stat1 in RVFV pathogenesis.


  • Open Access

    Modeling Neurodevelopmental Disorders and Epilepsy Caused by Loss of Function ofkif2ain Zebrafish

    by Michèle Partoens, Ann-Sofie De Meulemeester, Hoi-Khoanh Giong, Duc-Hung Pham, Jeong-Soo Lee, Peter A. de Witte, Aleksandra Siekierska

    In recent years there has been extensive research on malformations of cortical development (MCDs) that result in clinical features like developmental delay, intellectual disability, and drug-resistant epilepsy (DRE). Various studies highlighted the contribution of microtubule-associated genes (including tubulin and kinesin encoding genes) in MCD development. It has been reported thatde novomutations inKIF2A, a member of thekinesin-13family, are linked to brain malformations and DRE. Although it is known that KIF2A functions by regulating microtubule depolymerization via an ATP-driven process,in vivoimplications ofKIF2Aloss of function remain partly unclear. Here, we present a novelkif2aknock-out zebrafish model, showing hypoactivity, habituation deficits, pentylenetetrazole-induced seizure susceptibility and microcephaly, as well as neuronal cell proliferation defects and increased apoptosis. Interestingly,kif2a−/−larvae survived until adulthood and were fertile. Notably, ourkif2azebrafish knock-out model demonstrated many phenotypic similarities toKIF2Amouse models. This study provides valuable insights into the functional importance ofkif2ain zebrafish and phenotypical hallmarks related toKIF2Amutations. Ultimately, this model could be used in a future search for more effective therapies that alleviate the clinical symptoms typically associated with MCDs.


  • Open Access

    G3BPs tether the TSC complex to lysosomes and suppress mTORC1 signaling

    by Mirja Tamara Prentzell, Ulrike Rehbein, Marti Cadena Sandoval, Ann-Sofie De Meulemeester, Ralf Baumeister, Laura Brohée, Bianca Berdel, Mathias Bockwoldt, Bernadette Carroll, Suvagata Roy Chowdhury, et al.